share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP：信函
美股sec公告 ·  04/19 13:23
Moomoo AI 已提取核心信息
Apollomics Inc., a biopharmaceutical company, has addressed a comment from the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission (SEC) regarding its Registration Statement on Form F-3, initially filed on April 1, 2024. The SEC's comment, dated April 15, 2024, questioned the residency of the company's board of directors, specifically the discrepancy between the company's previous response and the disclosure that two directors are based in mainland China. Apollomics clarified that all board members reside outside of China and has amended the disclosure on page 22 of the Registration Statement accordingly. The amendment, known as Amendment No. 1, was filed via EDGAR. The company's legal representative, White & Case LLP, has invited the SEC to discuss any further questions or comments.
Apollomics Inc., a biopharmaceutical company, has addressed a comment from the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission (SEC) regarding its Registration Statement on Form F-3, initially filed on April 1, 2024. The SEC's comment, dated April 15, 2024, questioned the residency of the company's board of directors, specifically the discrepancy between the company's previous response and the disclosure that two directors are based in mainland China. Apollomics clarified that all board members reside outside of China and has amended the disclosure on page 22 of the Registration Statement accordingly. The amendment, known as Amendment No. 1, was filed via EDGAR. The company's legal representative, White & Case LLP, has invited the SEC to discuss any further questions or comments.
生物制药公司Apollomics Inc. 已经回应了美国证券交易委员会（SEC）公司财务部工作人员就其最初于2024年4月1日提交的F-3表格注册声明发表的评论。美国证券交易委员会于2024年4月15日发表的评论质疑公司董事会的驻地，特别是公司先前的回应与披露的两名董事在中国大陆的差异。Apollomics澄清说，所有董事会成员都居住在中国境外，并对注册声明第22页的披露进行了相应的修改。该修正案被称为第1号修正案，是通过EDGAR提交的。该公司的法定代表人White & Case LLP已邀请美国证券交易委员会讨论任何进一步的问题或评论。
生物制药公司Apollomics Inc. 已经回应了美国证券交易委员会（SEC）公司财务部工作人员就其最初于2024年4月1日提交的F-3表格注册声明发表的评论。美国证券交易委员会于2024年4月15日发表的评论质疑公司董事会的驻地，特别是公司先前的回应与披露的两名董事在中国大陆的差异。Apollomics澄清说，所有董事会成员都居住在中国境外，并对注册声明第22页的披露进行了相应的修改。该修正案被称为第1号修正案，是通过EDGAR提交的。该公司的法定代表人White & Case LLP已邀请美国证券交易委员会讨论任何进一步的问题或评论。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息